Oric Pharmaceuticals Inc
ORIC12.530USD
-0.160-1.26%
交易中 （美東）報價延遲15分鐘
1.08B總市值
虧損本益比TTM
關於 Oric Pharmaceuticals Inc 公司
ORIC Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司，致力於通過克服癌症耐藥性來改善患者的生活。該公司正在開發一系列臨牀和發現階段的療法，旨在通過利用其在三個特定領域的專業知識來對抗癌症的耐藥機制：激素依賴性癌症、精準腫瘤學和關鍵腫瘤依賴性。其臨牀階段候選產品包括 ORIC-114，一種腦滲透抑制劑，旨在選擇性靶向 EGFR 和 HER2，對外顯子 20 插入突變具有高效力，正在針對多種基因定義的癌症進行開發；ORIC-944，一種通過 EED 亞基的多梳抑制複合物 2 (PRC2) 的變構抑制劑，正在爲前列腺癌開發；以及 ORIC-533，一種口服生物可利用的小分子 CD73 抑制劑，CD73 是腺苷通路中的一個關鍵節點，被認爲在化療和免疫療法治療方案的耐藥性中起着核心作用。
Oric Pharmaceuticals Inc簡介
公司代碼ORIC
公司名稱Oric Pharmaceuticals Inc
上市日期Apr 24, 2020
CEODr. Jacob M. Chacko, M.D.
員工數量115
證券類型Ordinary Share
年結日Apr 24
公司地址240 E. Grand Ave
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94080
電話16503885600
網址https://oricpharma.com/
公司代碼ORIC
上市日期Apr 24, 2020
CEODr. Jacob M. Chacko, M.D.
Oric Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
528.65K
-14.61%
Dr. Richard A. (Rich) Heyman, Ph.D.
Dr. Richard A. (Rich) Heyman, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
261.57K
+14.34%
Dr. Kevin Brodbeck, Ph.D.
Dr. Kevin Brodbeck, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Dominic G. Piscitelli, CPA
Mr. Dominic G. Piscitelli, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
--
--
Mr. Steven L. (Steve) Hoerter
Mr. Steven L. (Steve) Hoerter
Independent Director
Independent Director
--
--
Dr. Lori A. Kunkel, M.D.
Dr. Lori A. Kunkel, M.D.
Independent Director
Independent Director
--
--
Dr. Angie J. You, Ph.D.
Dr. Angie J. You, Ph.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
528.65K
-14.61%
Dr. Richard A. (Rich) Heyman, Ph.D.
Dr. Richard A. (Rich) Heyman, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
261.57K
+14.34%
Dr. Kevin Brodbeck, Ph.D.
Dr. Kevin Brodbeck, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Dominic G. Piscitelli, CPA
Mr. Dominic G. Piscitelli, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月31日 週日
更新時間: 8月31日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Nextech Invest, Ltd.
7.37%
EcoR1 Capital, LLC
6.93%
VR Adviser, LLC
6.79%
Viking Global Investors LP
6.77%
Pfizer Inc
5.54%
其他
66.60%
持股股東
持股股東
佔比
Nextech Invest, Ltd.
7.37%
EcoR1 Capital, LLC
6.93%
VR Adviser, LLC
6.79%
Viking Global Investors LP
6.77%
Pfizer Inc
5.54%
其他
66.60%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
28.79%
Investment Advisor
26.63%
Venture Capital
22.65%
Hedge Fund
14.71%
Corporation
5.54%
Private Equity
2.02%
Sovereign Wealth Fund
1.98%
Research Firm
1.23%
Individual Investor
1.21%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
297
95.41M
98.24%
+8.51M
2025Q2
288
93.19M
110.15%
+12.20M
2025Q1
294
83.96M
99.59%
+456.78K
2024Q4
284
80.39M
113.18%
-3.73M
2024Q3
272
78.70M
112.04%
-2.29M
2024Q2
265
76.25M
113.03%
-1.57M
2024Q1
276
71.21M
105.62%
-1.02M
2023Q4
259
57.91M
108.09%
+1.21M
2023Q3
260
55.20M
103.62%
-1.09M
2023Q2
255
52.76M
117.11%
+8.95M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Nextech Invest, Ltd.
7.16M
7.37%
+1.88M
+35.51%
Jun 30, 2025
EcoR1 Capital, LLC
6.73M
6.93%
+5.11M
+315.81%
Jul 29, 2025
VR Adviser, LLC
6.60M
6.79%
--
--
Jun 30, 2025
Viking Global Investors LP
6.57M
6.77%
--
--
Jun 30, 2025
Pfizer Inc
5.38M
5.54%
--
--
Jun 30, 2025
SR One Capital Management, LP
4.62M
4.75%
+100.45K
+2.22%
Aug 12, 2025
New Enterprise Associates (NEA)
4.12M
4.24%
+1.92M
+87.59%
Jun 30, 2025
Alkeon Capital Management LLC
3.75M
3.86%
+409.32K
+12.25%
Jun 30, 2025
The Column Group LP
3.54M
3.65%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.43M
3.53%
-969.78K
-22.06%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
1.08%
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
SPDR S&P Biotech ETF
0.26%
Optimize Strategy Index ETF
0.25%
iShares Health Innovation Active ETF
0.15%
Direxion Daily S&P Biotech Bull 3X Shares
0.15%
iShares Micro-Cap ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
Fidelity Enhanced Small Cap ETF
0.08%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比1.08%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.9%
SPDR S&P Biotech ETF
佔比0.26%
Optimize Strategy Index ETF
佔比0.25%
iShares Health Innovation Active ETF
佔比0.15%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.15%
iShares Micro-Cap ETF
佔比0.15%
ProShares Ultra Nasdaq Biotechnology
佔比0.12%
Invesco Nasdaq Biotechnology ETF
佔比0.12%
Fidelity Enhanced Small Cap ETF
佔比0.08%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
